The doses were selected based on previous studies on the restoration of cardiopulmonary health in several animal disease models [32,33] and considering multiple factors, including the anticipated starting dose in humans, achieving a maximum feasible dose, the expression levels of ACE2 and Ang(1–7) in plant cells, and the integrity of the lyophilized plant cells in the dosing solutions. Here, ACE2 is linked to non-human animal disease.